Silydianin

Silydianin: A Comprehensive Encyclopedic Reference

1. Identity: Names, Source, and Chemical Character

1.1 Nomenclature

Silydianin (CAS No. 29782-68-1) is also known by the synonym silidianin. It is recognized in official pharmacopeial contexts as one of the quantified markers of standardized milk thistle dry extract. Its EC Number is 249-848-5.

1.2 Botanical Source

Silydianin is a plant secondary metabolite belonging to the group of polyphenols known as flavonolignans — formed by the coupling of a flavonoid with a phenylpropanoid (lignan) — and occurs typically in Silybum marianum (L.) Gaertn (milk thistle, Asteraceae) fruits (cypselae).

Silybum marianum is native to the Mediterranean region; it is a robust biennial herb characterized by large, glossy leaves with distinctive white marbling and striking purple-pink flower heads, growing up to 1.5 meters tall and well-adapted to dry, rocky soils. Native to the Mediterranean, Silybum marianum has since naturalized across much of Europe and beyond.

1.3 Chemical Identity

Silydianin has the molecular formula C₂₅H₂₂O₁₀ and a molecular weight of 482.44 g/mol. Flavonolignans are plant secondary metabolites formed by the coupling of a flavonoid with a phenylpropanoid (lignan). The structure of silydianin is unique among flavonolignans and somewhat complicated, but it is biosynthesized analogously to other silymarin flavonolignans by the radical coupling of taxifolin and coniferyl alcohol. The only substantial difference is in the radical coupling forming two new C–C bonds, creating a bicyclic structure and the fate of the primary alcoholic group of the coniferyl alcohol. In silydianin, intramolecular hemiacetalization occurs; thus, an unusual geminal ketone–hemiacetal structure is formed.

While it shares a similar biosynthetic pathway with other silymarin flavonolignans, the key difference lies in its formation: silydianin forms two new carbon–carbon (C–C) bonds, creating a unique bicyclic structure. Additionally, the primary alcohol group of coniferyl alcohol undergoes intramolecular hemiacetalization, resulting in this unusual geminal ketone–hemiacetal structure.

The structure of silydianin was initially resolved using X-ray diffraction data. Since the resolution of the original data was low, the misplacement of some atoms or bonds was possible.

Silydianin is a constitutional isomer of silybin A, silybin B, isosilybin A, isosilybin B, and silychristin — all of which share the same molecular formula.

The chemical structure of silymarin flavonolignan isomers corresponds to the molecular formula C₂₅H₂₂O₁₀. The oxeran ring is responsible for the biological activity of silymarin, and opening of this ring results in loss of activity. Only silybins and isosilybins contain the 1,4-dioxane ring system in their structure — a structural feature that distinguishes silydianin from those congeners.

1.4 Position within the Silymarin Complex

Silymarin represents 1.5–3% of the fruit's dry weight and is an isomeric mixture of unique flavonoid complexes — flavonolignans. The main representatives of this group presented in silymarin are silybin, isosilybin, silychristin, isosilychristin, silydianin, and silimonin.

Silybin, a main component of silymarin, accounts for about 60–70%, followed by silychristin (20%), silydianin (10%), and isosilybin (5%).

Phytochemical studies on silymarin have confirmed that it consists of several flavonolignan isomers, including silybin A (SBNA), silybin B (SBNB), isosilybin A (IBNA), isosilybin B (IBNB), silydianin (SDN), and silychristin (SCN). A standardized milk thistle dry extract is refined and quantified using the nominal silymarin percentage (in the range of 30.0–65.0%), which corresponds to the sum of SBNA, SBNB, IBNA, IBNB, SDN, and SCN concentrations according to the European Pharmacopoeia (EP 10.6).

According to the European Pharmacopoeia, the nominal silymarin content of the refined and quantified milk thistle dry extract is within the range of 30–65%. The content of silymarin corresponds to: (a) sum of the contents of silychristin and silydianin 20–45%, (b) sum of the contents of silybin A and silybin B 40–65%, (c) sum of the contents of isosilybin A and isosilybin B 10–20%. The extract should contain 90–110% of the nominal content of silymarin, expressed as silybin.

Silymarin is a complex mixture of flavonolignans including silybin A, silybin B, isosilybin, silychristin, silydianin, 2,3-dehydrosilybin, 2,3-dehydrosilychristin, and 2,3-dehydrosilydianin, the flavanonol taxifolin, and polymeric phenolics. Minor silymarin flavonolignans include 2,3-dehydrosilybin, 2,3-dehydrosilychristin, and 2,3-dehydrosilydianin.

1.5 Common Forms and Preparations

Milk thistle is available mainly as an extract prepared from the seeds of the plant. The two most common commercial preparations are termed silymarin and silibinin. Silydianin is not commercially marketed as an isolated supplement in consumer-facing products; it is instead encountered as a constituent of standardized silymarin extracts.

Because of its excellent therapeutic efficacies, silymarin is one of the most widely used dietary supplements, with around 75 brands available on the market in different dosage forms (tablets, capsules, syrups, etc.). Silymarin, a mixture of structural flavonolignan components (silybin A and B, silydianin, and silychristin) from Silybum marianum fruits, is marketed in many countries under the trademark Legalon™ or Hepatron™.

Its potential antiviral and gastrointestinal benefits have been largely underexplored, with scientists citing challenges in its isolation and purification as a key reason that silydianin is rarely encountered as a standalone isolate. Silydianin is available from chemical suppliers (e.g., Sigma-Aldrich) as a reference standard for analytical purposes, for use in research settings.

2. Traditional and Historical Use

2.1 Ancient Mediterranean World

Silymarin is an extract from the fruits of milk thistle (Silybum marianum (L.) Gaertn, Asteraceae), a medicinal plant used for various human ailments since the times of the ancient Greeks. Silymarin, an extract from the seeds of Silybum marianum (milk thistle), has been used for its hepatoprotective, antioxidant, anti-inflammatory, and anticancer properties for over 2,000 years.

Therapeutic properties of milk thistle were first documented by the Greek physician and botanist Dioscorides (in 40–90 AD). Not long after, the Roman naturalist Pliny the Elder echoed Dioscorides' observations in his Natural History, recommending milk thistle for "liver ailments" and even as a remedy for poisoning.

2.2 Medieval and Renaissance Europe

As the centuries rolled on, milk thistle's reputation spread across Europe. In medieval times, monks in monastic gardens cultivated it as a staple of their medicinal herb collections, using it to treat everything from jaundice to digestive issues.

In his book, Nicholas Culpeper noted silymarin's effectiveness for treating blockages in the spleen and liver. Early European colonists brought milk thistle to the Americas. By the early 20th century, herbalists used it to treat issues related to the kidneys, liver, spleen, and menstruation.

2.3 Modern Scientific Identification of Silydianin

Throughout this long history of use, the individual flavonolignan constituents — including silydianin — were unknown. The plant was used as a whole-seed or whole-plant preparation. Silymarin as a defined extract was first isolated by Wagner et al. in 1968. Interest in the healing properties of milk thistle continued until the 1960s, when German research renewed focus on its ability to treat liver disorders and protect the liver from harmful toxins.

Thanks to its healthful properties, silymarin — an extract of milk thistle fruits — was classified by the WHO in the 1970s as an official medicine with hepatoprotective properties. For decades, both experimental and clinical research was predominantly focused on a single component, silybin, while other related flavonolignans, such as silychristin, isosilybins, silydianin, dehydrosilybin, and the flavonoid taxifolin, have been understudied.

The regional isomer of silydianin, isosilydianin, was first reported by Arnone et al. in 1979.

2.4 Traditional Preparations

Traditional use of milk thistle — and therefore of the silymarin complex that includes silydianin — encompassed decoctions of the seeds and, in some traditions, consumption of the seeds themselves. Silymarin has been acknowledged from the ancient period and is utilized in European and Asian systems of traditional medicine for treating various liver disorders. The achenes of S. marianum are bitter in taste, cool in nature, and have the effects of clearing heat, protecting liver and gallbladder. They can be utilized for the treatment of jaundice, damp heat of the liver and gallbladder, as well as related conditions.

3. Key Constituents and Structural Context within the Silymarin Complex

3.1 Silydianin as a Flavonolignan

Formally, flavonolignans are derived from two phenylpropanoid units but have an additional structural part that places them under the flavonoids group. Silymarin is a group of flavonolignans including silybin, isosilybin, silydianin, and silychristin, which are formed through the dehydration-condensation process of dihydroflavonols and phenylpropanoid derivatives to produce flavonolignan compounds.

Flavonolignans in Silybum marianum are structurally diverse constituents isolated from its fruits and seeds that have been found to exhibit antioxidant, lipid-lowering, antihypertensive, antidiabetic, antiatherosclerotic, and anti-obesity properties.

3.2 The Oxidation Derivative: 2,3-Dehydrosilydianin

The oxidation product of silydianin, 2,3-dehydrosilydianin, characterized by a 2,3 double bond, has been shown to be more active than silybin, particularly in anticancer and antioxidant activities. Structure–activity relationship studies suggest that the presence of a 2,3 double bond or phenolic hydroxyl group enhances biological activity.

3.3 Relative Antioxidant Capacity

A detailed comparison of antioxidant properties among the main silymarin components further revealed that taxifolin, silychristin, and silydianin all exhibited stronger radical scavenging activity than silybin in DPPH, ORAC, and ABTS+ assays, with taxifolin showing by far the most potent effect — its EC₅₀ values were approximately 10-fold lower than those of silybin. This finding is important because it challenges the long-held assumption that silybin is the primary antioxidant driver within the silymarin complex.

4. Established and Proposed Mechanisms of Action

4.1 Antioxidant and Free Radical Scavenging

The inhibitory effect of silydianin, an active constituent of Silybum marianum, on the in vitro production and release of oxidative products has been examined. Induction of apoptosis by silydianin was accompanied by a decrease in luminol-enhanced chemiluminescence as well as superoxide radical (O₂·⁻) release in freshly isolated cells and lipid peroxidation in mouse spleen microsomes.

Silymarin (including silydianin as a constituent) protects liver cell membranes against hepatotoxic agents and improves liver function in experimental animals and humans. It is generally accepted that silymarin exerts a membrane-stabilizing action preventing or inhibiting membrane peroxidation. Experiments with soybean lipoxygenase showed that the three components of silymarin — including silydianin — brought about a concentration-dependent non-competitive inhibition of lipoxygenase. The experiments also showed an analogous interaction with animal lipoxygenase, thus showing that an inhibition of the peroxidation of fatty acids in vivo was evident.

4.2 Anti-Inflammatory Mechanisms

Results of in vitro studies indicate a possible anti-inflammatory activity for silydianin, which regulates caspase-3 activation, affects cell membranes, and acts as a free radical scavenger.

Silymarin, a mixture of flavonolignans comprising mainly silybin, silydianin, and silychristin, exhibited significant anti-inflammatory and antiarthritic activities in a papaya latex-induced model of inflammation and mycobacterial adjuvant-induced arthritis in rats, with results indicating its action through inhibition of 5-lipoxygenase.

Mechanistic studies have clarified that silymarin's major bioactive constituents, like silibinin, silydianin, and silychristin, interact with redox-sensitive transcriptional pathways such as Nrf2/ARE and NF-κB, while also influencing metabolic regulators like AMPK and SIRT1.

4.3 Modulation of Apoptosis and Neutrophil Biology

Polymorphonuclear neutrophils (PMNs) play a primary role in the initiation and propagation of inflammatory responses. Their apoptosis is a major mechanism associated with the resolution of inflammatory reactions. Neutrophils were assessed for caspase-3 activity, the first step in the execution phase of apoptosis. When cells were cultured with 100 µM silydianin for 24 hours, caspase-3 was activated. Induction of apoptosis by silydianin was accompanied by a decrease in luminol-enhanced chemiluminescence as well as superoxide radical release in freshly isolated cells and lipid peroxidation in mouse spleen microsomes.

No significant effect of silydianin on PMN hydrogen peroxide production evaluated by a flow cytometric dichlorofluorescin oxidation assay was found, indicating that silydianin's antioxidant actions in this context are selective rather than blanket suppressors of all oxidant species.

4.4 Enzyme Inhibition

Functioning as a modulator, silydianin is postulated to influence the behavior of several enzymes and proteins. Scientific investigations have revealed its potential to inhibit the activity of enzymes associated with inflammation, such as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX). Furthermore, silydianin displays inhibitory effects on proteins that regulate cellular processes like proliferation and apoptosis, including Bcl-2 and caspase-3. It is important to note that many of these specific claims rest on in vitro evidence only, and independent replication specifically for silydianin (as distinct from the silymarin mixture) is limited.

4.5 In Vivo Antioxidant Perspective

In vivo, silymarin flavonolignans do not act as redox antioxidants, but they play a role as specific ligands of biological targets, according to the "lock-and-key" concept. Estrogenic, antidiabetic, anticancer, antiviral, and antiparasitic effects have been demonstrated in optically pure flavonolignans. Potential application of pure flavonolignans has also been shown in cardiovascular and neurological diseases.

5. Scientific Evidence by Area of Use

A critical point in evaluating the scientific evidence for silydianin is that silymarin, an extract from the seeds of milk thistle (Silybum marianum), has been widely studied and used for its hepatoprotective and pharmacological properties. For decades, both experimental and clinical research has been predominantly focused on a single component, silybin, while other related flavonolignans, such as silychristin, isosilybins, silydianin, dehydrosilybin, and the flavonoid taxifolin, have been understudied. The consequence is that very few human clinical trials or even robust animal studies have been conducted with isolated silydianin; the majority of evidence derives from studies of the whole silymarin complex or from in vitro experiments with purified silydianin.

5.1 Antioxidant and Free Radical Scavenging Activity

Evidence type: In vitro (cell-free and cell-based assays)

The most direct published evidence specific to silydianin as an isolate concerns its antioxidant properties. The inhibitory effect of silydianin on the in vitro production and release of oxidative products has been examined. In the 2006 study by Zielińska-Przyjemska and Wiktorowicz (published in Phytotherapy Research), silydianin at 100 µM was tested on isolated human neutrophils. When cells were cultured with 100 µM silydianin for 24 hours, caspase-3 was activated. Induction of apoptosis by silydianin was accompanied by a decrease in luminol-enhanced chemiluminescence as well as superoxide radical (O₂·⁻) release in freshly isolated cells and lipid peroxidation in mouse spleen microsomes. These findings suggest that silydianin simultaneously promotes the resolution of inflammation (via neutrophil apoptosis) and suppresses oxidant production.

In comparative antioxidant assays, taxifolin, silychristin, and silydianin all exhibited stronger radical scavenging activity than silybin in DPPH, ORAC, and ABTS+ assays. This is a notable finding given the historical tendency to ascribe antioxidant potency primarily to silybin.

Evidence strength: Preliminary. All findings are in vitro. No human trials with isolated silydianin exist for this indication.

5.2 Hepatoprotective Activity

Evidence type: Silymarin mixture (clinical); silydianin-specific (in vitro only)

Silymarin, a principal bioactive constituent of milk thistle extract, is recognized for its supportive role in the therapeutic management of hepatic disorders, including acute viral hepatitis, alcoholic liver disease, and chemically-induced liver toxicity. As a constituent of silymarin, silydianin participates in the collective hepatoprotective action of the extract.

Silymarin is used in Europe to treat all types of liver disorders. Silymarin is applicable for acute and chronic hepatitis of varying causes. Patients with acute viral hepatitis treated with silymarin show greater improvements in serum levels of bilirubin and liver enzymes compared with those treated with placebo.

The hepatoprotective effect of silymarin results from its numerous biological activities (e.g., antioxidative, antifibrotic, anti-lipid peroxidative, anti-inflammatory, and immunomodulatory activities) as well as involvement in liver regeneration mechanisms.

The uses and applications of silydianin are predominantly centered around its hepatoprotective effects. It is widely studied for its therapeutic potential in treating liver-related disorders, including cirrhosis, hepatitis, and fatty liver disease. Additionally, silydianin is being explored for its beneficial roles in counteracting oxidative stress and inflammation, with implications for broader applications in metabolic syndrome and related conditions.

Evidence strength: For the whole silymarin extract, clinical evidence supporting hepatoprotective use exists, but is still considered moderate in quality (many trials are small and methodologically heterogeneous). For silydianin specifically as an isolated compound, no human clinical trials have been published. The contribution of silydianin individually to hepatoprotective outcomes in clinical silymarin studies cannot be separated from the other constituents.

5.3 Anti-inflammatory and Antiarthritic Activity

Evidence type: In vitro; animal models

Silymarin, a mixture of flavonolignans comprising mainly silybin, silydianin, and silychristin, exhibited significant anti-inflammatory and antiarthritic activities in the papaya latex-induced model of inflammation and mycobacterial adjuvant-induced arthritis in rats. Results of the study indicate its action through inhibition of 5-lipoxygenase for anti-inflammatory and antiarthritic activities.

The anti-gastric ulcer activity of silymarin is attributed to its inhibition of enzymatic peroxidation in the lipoxygenase pathway, which inhibits leukotriene synthesis. Silymarin has free radical scavenging activity. It can also regulate the arachidonic acid cascade and inhibit the production of prostaglandins and leukotrienes, thus effectively inhibiting the development of arthritis.

Evidence strength: Preclinical (in vitro and animal). These studies used the silymarin mixture rather than isolated silydianin. No human clinical trials for anti-inflammatory or antiarthritic effects of silydianin specifically have been published.

5.4 Antiviral Activity

Evidence type: In vitro (cell-based antiviral assays); animal models

A 2025 PMC-indexed study directly investigated a silydianin-rich extract from Silybum marianum seeds. This study investigated the effects of a silydianin-rich extract from Silybum marianum seeds on enteroviral infections in vitro and the mitigation of delayed gastric emptying in mice. The study assessed cytotoxicity and antiviral activity of the extract at various stages of the viral life cycle, including virucidal activity, cell protection, and post-infection effects, using neutral red assays in RD cells, with results confirmed by real-time PCR. The viruses studied included coxsackievirus B2, coxsackievirus A10, poliovirus SL-1, and enterovirus EV71.

The silydianin-rich extract showed consistent antiviral activity, with the highest selectivity index (SI) for EV71 (4.08) during virucidal activity. It provided moderate cell protection, with EC₅₀ values ranging from 120.88 to 186.10 µg/mL and SI values from 2.20 to 3.39. Post-infection treatment showed varying efficacy, with coxsackie A10 demonstrating the highest SI (3.90).

The impact on delayed gastric emptying was evaluated in a mouse model using doses of 100 and 200 mg/kg compared to a control group receiving physiological saline.

Recent studies have also documented the antiviral activities of silymarin and its derivatives against several viruses, including the flaviviruses (hepatitis C virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus), influenza virus, human immunodeficiency virus, and hepatitis B virus. However, these broader antiviral findings are for the whole silymarin complex rather than silydianin in isolation.

Notably, biological activity studies of silydianin are limited, and its antiviral potential, particularly against the enteroviruses studied, had not previously been characterized.

Evidence strength: Preliminary in vitro and animal data. The antiviral work used a silydianin-rich extract, not fully purified silydianin, and all results are preclinical. No human clinical trials for antiviral activity of silydianin have been published.

5.5 Photoprotective and Dermatological Activity

Evidence type: In vitro (cell-based assays with human cells)

Researchers aimed to investigate the UVA-protective effects of silymarin's less abundant flavonolignans, specifically isosilybin (ISB), silychristin (SC), silydianin (SD), and 2,3-dehydrosilybin (DHSB). Normal human dermal fibroblasts (NHDF) pre-treated for 1 hour with flavonolignans were then exposed to UVA light using a solar simulator. Their effects on reactive oxygen species (ROS), carbonylated proteins and glutathione (GSH) level, caspase-3 activity, single-strand breaks' (SSBs) formation, and protein level of matrix metalloproteinase-1 (MMP-1), heme oxygenase-1 (HO-1), and heat shock protein (HSP70) were evaluated.

The most pronounced preventative potential was found for 2,3-dehydrosilybin (DHSB), a minor component of silymarin, and silychristin (SC), the second most abundant flavonolignan in silymarin. They had significant effects on most of the studied parameters. Silydianin showed a more limited photoprotective profile compared to dehydrosilybin and silychristin in this pilot study.

Unlike silybin, isosilybin, silychristin, and silydianin, 2,3-dehydrosilybin was identified as a compound with phototoxic potential in normal human dermal fibroblasts, normal human epidermal keratinocytes, and the HaCaT cell line. This is a safety-relevant finding: silydianin was specifically identified as non-phototoxic in this in vitro comparison.

In a separate topical delivery study, silybin (SB), silydianin (SD), and silychristin (SC) are components of silymarin. These compounds can be used to protect the skin from oxidative stress induced by ultraviolet (UV) irradiation and treat it. To this end, the absorption of silymarin constituents via the skin was examined. Transport of SB, SD, and SC under the same thermodynamic activity through and into the skin and the effects of pH were studied in vitro using a Franz diffusion assembly. The lipophilicity increased in the order SC < SD < SB. Increased lipophilicity of a compound resulted in higher skin deposition but had a minor effect on permeation across the skin in the less-ionized form (pH 8).

Evidence strength: Preliminary in vitro findings. The photoprotection study was explicitly described as a pilot study; no clinical (human skin) trials for silydianin photoprotection exist. The topical penetration data provide useful mechanistic context but are not clinical evidence of efficacy.

5.6 Anticancer Activity

Evidence type: Preliminary in vitro; no human clinical trials for isolated silydianin

Silydianin is one of the main active constituents of Silybum marianum, with an ability of scavenging free radicals, reducing oxidative stress, and also has anti-inflammatory and metabolic regulating effects. Preliminary studies have shown that silydianin may have the potential to inhibit the growth of certain tumor cells.

Silymarin has antioxidant and hepatoprotective effects, as well as anticancer, chemoprotective, dermatoprotective, and hypocholesterolemic activities. However, less known components of silymarin may possess unique or even superior pharmacological activities compared to silybin, including strong antioxidant, anti-inflammatory, antiviral, and selective anticancer effects.

The oxidation product of silydianin, 2,3-dehydrosilydianin, characterized by a 2,3 double bond, has been shown to be more active than silybin, particularly in anticancer and antioxidant activities. This suggests that silydianin itself may serve as a biosynthetic or metabolic precursor to more potent anti-cancer species in vivo, though this has not been established in humans.

Evidence strength: Highly preliminary. All specific anticancer findings for silydianin rely on in vitro models. Clinical evidence for anti-cancer effects comes from studies of the whole silymarin mixture or silybin, not silydianin in isolation.

5.7 Cardiovascular-Related Activities

Evidence type: In vitro; animal models (attributed to silymarin complex)

Pre-clinical studies including in vitro tests or animal models have predominantly implicated the following effects of silymarin and its constituents: (1) antioxidant, (2) hypolipidemic, (3) hypoglycemic, (4) anti-hypertensive and (5) cardioprotective. Silydianin, as a constituent of silymarin, may contribute to these effects, but its individual contribution has not been formally isolated.

Estrogenic, antidiabetic, anticancer, antiviral, and antiparasitic effects have been demonstrated in optically pure flavonolignans. Potential application of pure flavonolignans has also been shown in cardiovascular and neurological diseases.

Evidence strength: Preclinical only, and principally attributable to the silymarin complex or silybin rather than to silydianin specifically. No human clinical data for cardiovascular outcomes from silydianin exist.

6. Body Systems and Health Areas Associated with Silydianin

• Hepatic/Liver System: The active ingredient of milk thistle, located in seeds, consists of three flavolignans — silybin, silydianin, and silychristin, collectively termed silymarin. Silymarin is used in Europe to treat all types of liver disorders.
• Immune/Inflammatory System: Silydianin regulates caspase-3 activation in neutrophils, affects cell membranes, and acts as a free radical scavenger, indicating possible anti-inflammatory activity.
• Skin/Dermatological System: Silybin, silydianin, and silychristin are components of silymarin that can be used to protect the skin from oxidative stress induced by UV irradiation.
• Gastrointestinal System: A study investigating the effects of a silydianin-rich extract on enteroviral infections and delayed gastric emptying found relevant activity in mice, though silydianin had not been extensively studied for gastroparesis prior to this work.
• Antiviral/Infectious Disease: Studies have documented antiviral activities of silymarin and its derivatives against several viruses, including hepatitis C virus, dengue virus, chikungunya virus, influenza virus, HIV, and hepatitis B virus — a body of evidence from which silydianin cannot yet be individually distinguished.
• Metabolic/Endocrine System: The crude extract silymarin is used in a plethora of nutraceutical preparations and drugs, mainly for its hepatoprotective action; nonetheless, it also exerts cardioprotective, hypocholesterolemic, and antidiabetic activities.
• Nervous System: Silymarin, a phytocomplex of Silybum marianum, has emerged as one of the most mechanistically characterized botanical agents in hepatoprotective and neuroprotective therapy.

7. Dosage Forms and Dosages Reported in Studies

7.1 Silymarin (Complex Containing Silydianin) — Reported Clinical Dosages

Because silydianin is not available as a standalone clinical-use supplement, dosages from published research refer to the silymarin complex. Despite the therapeutic benefits of silymarin, it is used at high doses (280–1,000 mg) due to its low aqueous solubility (50–430 µg/mL), low bioavailability (23–47%), and limited absorption properties.

Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks. Some gastrointestinal discomforts occurred, like nausea and diarrhea.

Daily doses of silymarin up to 1,500 mg have been reported to be well tolerated.

7.2 Silydianin-Specific Dosages in Preclinical Research

When cells were cultured with 100 µM silydianin for 24 hours, caspase-3 was activated in the in vitro neutrophil study by Zielińska-Przyjemska and Wiktorowicz (2006).

The impact on delayed gastric emptying was evaluated in a mouse model using doses of 100 and 200 mg/kg (of the silydianin-rich extract) compared to a control group receiving physiological saline.

Cell protection in the antiviral in vitro study was measured with EC₅₀ values ranging from 120.88 to 186.10 µg/mL and selectivity index (SI) values from 2.20 to 3.39.

No human dosing regimens for isolated silydianin have been established or reported in clinical literature.

7.3 Formulation Challenges Affecting Silydianin Delivery

Silymarin (and by extension its constituent flavonolignans) has low water solubility, low gastric absorption, and a severe first-pass effect, resulting in poor bioavailability and unpredictable efficacy. Recent advances in formulation science have aimed to overcome these shortcomings.

An important challenge in the manufacturing of silymarin-based products is the poor aqueous solubility of flavonolignans.

Researchers are improving the bioavailability of silymarin through nanocrystals, nanosuspensions, solid dispersions, and complexes of cyclodextrins and phospholipids. In particular, the combination of silymarin with phosphatidylcholine increased the bioavailability of silymarin 4.6-fold compared to the extract alone.

8. Metabolism and Biotransformation

8.1 Gut Microbiota Biotransformation

Biotransformation of individual silymarin components by human microbiota was studied ex vivo, using batch incubations inoculated by fecal slurry. Samples at selected time points were analyzed by ultrahigh-performance liquid chromatography equipped with mass spectrometry. The initial experiment using a concentration of 200 mg/L showed that flavonolignans are resistant to the metabolic action of intestinal microbiota.

At the lower concentration of 10 mg/L, biotransformation of flavonolignans was much slower than that of taxifolin, which was completely degraded after 16 hours. Silydianin, 2,3-dehydrosilychristin, and 2,3-dehydrosilydianin were reduced under these experimental conditions, indicating a reductive metabolic pathway distinct from the demethylation seen with other silymarin components.

8.2 Phase II Metabolism

Silymarin is a component of a plethora of food supplements and over-the-counter drugs; however, the pharmacological properties of its pure constituents have been studied to only a limited extent. Sulfated and glucuronidated metabolites of flavonolignans including silydianin have been studied in the context of Phase II conjugation reactions, forming the basis of their urinary and biliary excretion, though the specific biotransformation products of silydianin specifically are not well characterized in humans.

9. Notable Safety Considerations and Drug Interactions

9.1 Safety Profile of Silydianin Specifically

Silybin, silydianin, and silychristin were not cytotoxic and genotoxic at a concentration of 100 µM in the referenced safety assessment — an important finding establishing in vitro non-toxicity at concentrations used in experimental studies.

Unlike silybin, isosilybin, silychristin, and silydianin, 2,3-dehydrosilybin was identified as a compound with phototoxic potential in normal human dermal fibroblasts, normal human epidermal keratinocytes, and the HaCaT cell line. This comparison explicitly characterizes silydianin as non-phototoxic in in vitro skin cell models — a favorable finding for any potential topical or oral use under sunlight exposure.

9.2 Safety of the Silymarin Complex (Which Contains Silydianin)

Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks. Some gastrointestinal discomforts occurred, like nausea and diarrhea.

Silymarin has no major toxicity in animals. Silymarin was mutagenic in Salmonella typhimurium strains in the presence of metabolic enzymes — an in vitro genotoxicity signal that has not translated into observed mutagenicity concerns in animal or human studies at therapeutic doses.

9.3 Drug Interactions — Cytochrome P450 and CYP2C9

Two commercially available formulations exist: the crude extract, silymarin, and the semipurified product, silibinin. Silymarin consists of at least seven flavonolignans, of which the most prevalent are the diastereoisomers silybin A and silybin B; silibinin consists only of silybin A and silybin B.

Drug interaction data for silydianin specifically are very limited. Broader silymarin interaction research has shown CYP enzyme inhibition as a class effect. Inhibition of drug-metabolizing enzymes and modulation of multidrug resistance activity by silymarin flavonolignans are discussed in the scientific literature, though the specific contribution of silydianin to these interactions has not been isolated from the effects of the mixture.

9.4 Bioavailability as a Safety-Relevant Factor

It is known that flavonolignans have poor and irregular bioavailability. The absorption rate of silymarin varies between 20 and 50%. The low and variable bioavailability of silydianin within the silymarin complex means that systemic exposure to this specific compound following oral administration of standard silymarin products is likely to be low and unpredictable, which limits both its therapeutic potential and its toxicological risk in conventional supplement use.

10. Research Status and Future Directions

Current advances in isolation, synthesis, and analytical methods now enable a systematic investigation of less known silymarin compounds. Less known components of silymarin may possess unique or even superior pharmacological activities compared to silybin, including strong antioxidant, anti-inflammatory, antiviral, and selective anticancer effects. Exploring these other constituents beyond silybin may unlock new opportunities for drug discovery and personalized phytotherapy, ultimately advancing the development of next-generation flavonolignan-based therapeutics.

Further studies should individually address the main constituents of silymarin which are responsible for the biological activity and determine potential neutral, synergistic, and antagonistic effects between these compounds. The inclusion of purified constituents from the silymarin mixture is needed to clarify the bioactivities of the respective compounds in future studies.

Silydianin, a key bioactive compound known for its liver-protective and antioxidant properties, has not been extensively studied for its impact on enteroviral infections and gastroparesis — nor, more broadly, for most of the health areas with which the silymarin complex is associated. The compound remains one of the more pharmacologically undercharacterized members of a well-studied extract, and the field is at a very early stage of understanding its independent contributions to health outcomes.

References

• Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.) — Chemistry, Bioavailability, and Metabolism (PMC6150307)
• Biotransformation of Silymarin Flavonolignans by Human Fecal Microbiota (PMC7023230)
• Determination of Flavonolignan Compositional Ratios in Silybum marianum Extracts Using HPLC (PMC11243550)
• Two Flavonolignans from Milk Thistle Inhibit CYP2C9-Mediated Warfarin Metabolism (PMC2835426)
• Sulfated Metabolites of Flavonolignans and 2,3-Dehydroflavonolignans: Preparation and Properties (PMC6121260)
• Looking beyond silybin: the importance of other silymarin flavonolignans (PMC12320500)
• In Vitro Antiviral Activity of a Silydianin-Rich Extract from Silybum marianum Seeds Against Four Strains of Enteroviruses (PMC11851915)
• An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species (PubMed 16444663)
• Antiviral Activities of Silymarin and Derivatives (PMC6514695)
• Silymarin, a Popular Dietary Supplement Shows Anti-Candida Activity (PMC6963672)
• A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin (PMC9145573)
• Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners (PMC8346157)
• Mechanistic Insights into the Pharmacological Significance of Silymarin (PMC9414257)
• Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications (PMC12695834)
• A pilot study of the UVA-photoprotective potential of dehydrosilybin, isosilybin, silychristin, and silydianin on human dermal fibroblasts (Arch Dermatol Res 2019)
• Topical delivery of silymarin constituents via the skin route (Acta Pharmacologica Sinica 2009)
• Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase (ScienceDirect)
• Recent advances in the analysis of flavonolignans of Silybum marianum (ScienceDirect)
• Superior silybin bioavailability of silybin-phosphatidylcholine complex in healthy volunteers (PMC6330464)
• Clinical and Regulatory Status of Silymarin (ResearchGate)
• Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats (PMC8146637)
• Silydianin — PubChem CID 11982272 (NIH/NLM)
• A review of the botany, phytochemistry, pharmacology, synthetic biology and comprehensive utilization of Silybum marianum (Frontiers in Pharmacology 2024)
• Silymarin as a phytopharmaceutical agent: advances in mechanistic insights (Frontiers in Pharmacology 2025)
• Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies (PMC12736914)
• Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies (PMC10610370)
• Characterization of metabolites from milk thistle flavonolignans generated by human fecal microbiota (ScienceDirect 2023)
• Advances in pharmacological studies of silymarin (PubMed 1842018)
• Flavonolignan — an overview (ScienceDirect Topics)
• Silidianin — an overview (ScienceDirect Topics)